Cancer treatment waiting times in mid and south Essex are under intense scrutiny, with a local Member of Parliament urging the government to provide “special” assistance to address what he describes as the worst performance of any trust in England. The concerns center around the percentage of cancer patients beginning treatment within the nationally mandated 62-day timeframe following referral.
The Mid and South Essex NHS Foundation Trust (MSEFT) is facing significant challenges in meeting cancer treatment targets. According to data covering the 12 months to November 2025, only 45.5% of cancer patients within the trust began treatment within 62 days of referral. This figure falls considerably short of the government’s aim of 85% and represents a substantial gap compared to other trusts across the country. The situation has prompted calls for increased investment and recruitment of specialist staff.
Urgent Need for Investment and Specialist Staff
Sir John Whittingdale, the Conservative MP for Maldon, has formally requested government intervention to improve the situation at MSEFT. He emphasized the need for additional funding to bolster the trust’s capacity, specifically highlighting a shortage of radiotherapists, and oncologists. “Those targets represent a massive leap from where we are now and it will need investment,” Sir John stated, according to reports. “In particular, it will need to recruit more specialists. We don’t have anything like the necessary number of radiotherapists or oncologists.”
The MSEFT oversees acute hospitals in Broomfield (Chelmsford), Southend, and Basildon. While the trust acknowledges the need for improvement, it reports that progress has been made in certain cancer types. Still, the overall performance remains a significant concern, with Sir John Whittingdale warning of potential consequences, including an increase in preventable deaths. “Sadly, we will have more counts of deaths than we need,” he said.
Broader Concerns About Elective Care and Hospital Performance
The challenges faced by MSEFT are not isolated. Labour MP Jen Craft has also raised concerns about the trust’s performance, citing cancelled procedures and an “unacceptable standard of care.” Reports indicate that constituents have expressed deep worry about delays in receiving necessary treatment. The trust was ranked the worst-performing large trust in England, and is currently falling short of government targets for 18-week waiting times for elective care, with only 50.4% of patients seen within that timeframe as of June 2025, down from 52.8% in November 2024.
One patient, David Brading, 69, from South Ockendon, described his experience as “awful,” detailing years of waiting for hip and knee replacements and the impact of cancelled orthopaedic procedures on his quality of life. The trust has acknowledged issues with theatre closures due to urgent estate work, impacting approximately 1,400 patients awaiting hip and knee treatment by the end of the year. Plans are underway to open two new orthopaedic theatres at Basildon Hospital this autumn.
Investment in Radiotherapy Capacity
Despite the broader challenges, there have been some positive developments in cancer care within the region. A new £5.3 million radiotherapy unit officially opened at Southend Hospital in May 2025, equipped with an advanced LINAC radiotherapy machine. This technology allows for more precise and tailored cancer treatments, minimizing damage to healthy tissue. The new unit is already in use, with 20 patients having received treatment since February.
David Burton-Sampson MP, representing Southend West and Leigh, hailed the new facility as “an exciting step forward for cancer care in Southend,” emphasizing the importance of cutting-edge technology in improving patient outcomes.
Looking Ahead
The situation in mid and south Essex underscores the ongoing pressures facing the NHS in delivering timely cancer care. While the new radiotherapy unit represents a positive step, addressing the systemic issues contributing to long waiting times will require sustained investment, increased staffing levels, and ongoing efforts to improve efficiency. The government’s commitment to improving cancer survival rates – aiming for three-quarters of patients to survive for at least five years by 2035 – will depend on successfully tackling these challenges. Further monitoring of MSEFT’s performance and the impact of planned improvements will be crucial in the coming months.
What are your thoughts on the challenges facing cancer care in the UK? Share your comments below and help us continue the conversation.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
